Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis

Journal of Clinical Investigation

Volumn 108, Issue 10, 2001, Pages 1411-1415

  Tan, E M ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; BINDING PROTEIN; MESSENGER RNA; PROTEIN P53;

AUTOIMMUNITY; CANCER; CARCINOGENESIS; DIAGNOSTIC VALUE; DISEASE MARKER; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMORAL IMMUNITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MOTIF; REVIEW; RNA BINDING; TUMOR IMMUNITY;

EID: 0035189977     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI14451     Document Type: Review

References (50)

1. Antinuclear antibodies: Diagnostic markers for autoimmune diseases and probes for cell biology
2. Autoimmune type 1 diabetes: Resolved and unresolved issues
3. Thyroid autoimmunity
4. Interplay between genetics and the environment in the development of celiac disease: Perspectives for a healthy life
5. HuD, a paraneoplastic encephalomyelitis antigen, contains RNA-binding domains and is homologous to Elav and sex-lethal
6. Onconeural antigens and the paraneoplastic disorders: At the intersection of cancer, immunity and the brain
7. What is missing in immunology to understand immunity?
8. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells
9. Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse
10. p53 mutations in human cancer
11. Participation of p53 protein in the cellular response to DNA damage
12. Surfing the p53 net
13. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer
14. Antibodies in the sera of patients with various types of cancer: A review
15. Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass
16. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutations
17. Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: Distribution on primary structure and exposure on protein surface
18. Analysis of the anti-p53 antibody response in cancer patients
19. Two distinct mechanisms alter p53 in breast cancer: Mutation and nuclear exclusion
20. Antinuclear antibodies (ANAs): Diagnostically specific immune markers and clues towards the understanding of systemic autoimmunity
21. Human tumor antigens recognized by Tlymphocytes
22. Increasing titers and changing specificities of antinuclear antibodies in patients with chronic liver disease who develop hepatocellular carcinoma
23. Serum p53 antibodies as early markers of lung cancer
24. Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer
25. Relation of the hepatitis B virus carrier state to hepatocellular carcinoma
26. Novel nuclear autoantigen with splicing factor motifs identified with antibody from hepatocellular carcinoma
27. A cell-cycle nuclear autoantigen containing WD-40 motifs expressed mainly in S and G2 phase cells
28. WD40 repeat proteins striatin and SG2 nuclear autoantigen are members of a novel family of calmodulin-binding proteins that associate with protein phosphatase 2A
29. Transcription activating property of autoantigen SG2NA and modulating effect of WD-40 repeats
30. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens
31. Immune response to cyclin B1 in hepatocellular carcinoma
32. A novel cytoplasmic protein with RNA-binding motifs is an autoantigen in human hepatocellular carcinoma
33. A family of insulin-like growth factor II mRNA binding proteins represses translation in late development
34. Cloning of a gene highly expressed in cancer coding for a novel KH-domain containing protein
35. Amplification in human breast cancer of a gene encoding a c-myc mRNA binding protein
36. The c-myc coding region determinant binding protein; a member of a family of KH domain RNA binding proteins
37. Insulin-like growth factors: The unrecognised oncogenes
38. Differential expression of insulin-like growth factor II mRNA in human primary liver cancers, benign liver tumors and liver cirrhosis
39. Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor II transgenic mice
40. A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis
41. Multiple oncogenes and tumor suppressor genes are structurally and functionally intact during hepatocarcinogenesis in hepatitis B transgenic mice
42. Aberrant expression of fecal RNA-binding protein p62 in liver cancer and liver cirrhosis
43. Why is Hu where? Shuttling of early response gene messenger RNA subsets
44. A serological marker of paraneoplastic limbic and brain stem encephalitis in patients with testicular cancer
45. The expression of the Hu (paraneoplastic encephalomyelitis/sensory neuronopathy) antigen in human normal and tumor tissues
46. Autoantibodies in cancer patients and in persons with a higher risk of cancer development
47. The hallmarks of cancer
48. De novo humoral immune response to cancer-associated autoantigens during transition from chronic liver disease to hepato-cellular carcinoma
49. p53 as a target for cancer vaccines: Recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor challenge